Drugs / Budesonide/formoterol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04191434 Comparator | Jul 2022 → May 2023 | asthma | EMS | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide/formoterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04191434 ↗ |
| Known as | Budesonid/formoterol | “Budesonid/formoterol 200/6 capsule” NCT04191434 ↗ |
| Route | Inhaled | “The participant must inhale 2 (two) capsules twice a day (12/12h)” NCT04191434 ↗ |